Stratum corneum removal facilitates experimental sensitization to mite allergens in atopic dogs

Veterinary Dermatology

Volumn 22, Issue 2, 2011, Pages 188-196

  Olivry, Thierry ^a   Wofford, Jessica ^a   Paps, Judy S ^a   Dunston, Stanley M ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CD30 ANTIGEN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; BIOSYNTHESIS; BLOOD; CD4+ T LYMPHOCYTE; DERMATOPHAGOIDES FARINAE; DOG; DOG DISEASE; EPIDERMIS; FEMALE; IMMUNOLOGY; INTRACUTANEOUS TEST; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PILOT STUDY;

ALLERGENS; ANIMALS; ANTIGENS, CD30; ANTIGENS, DERMATOPHAGOIDES; CD4-POSITIVE T-LYMPHOCYTES; DERMATITIS, ATOPIC; DERMATOPHAGOIDES FARINAE; DOG DISEASES; DOGS; EPIDERMIS; FEMALE; IMMUNOGLOBULIN E; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTRADERMAL TESTS; LYMPHOCYTE ACTIVATION; MALE; PILOT PROJECTS;

ACARI; CANIS FAMILIARIS; DERMATOPHAGOIDES; DERMATOPHAGOIDES FARINAE; PYROGLYPHIDAE;

EID: 79952348135     PISSN: 09594493     EISSN: 13653164     Source Type: Journal    
DOI: 10.1111/j.1365-3164.2010.00938.x     Document Type: Article

References (51)

1. Madison KC. Barrier function of the skin: "la raison d'être" of the epidermis. Journal of Investigative Dermatology 2003; 121: 231-41.
2. Elias PM, Schmuth M. Abnormal skin barrier in the etiopathogenesis of atopic dermatitis. Current Opinion in Allergy and Clinical Immunology 2009; 9: 437-46.
3. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. Journal of Allergy and Clinical Immunology 2008; 121: 1337-43.
4. Cork MJ, Danby SG, Vasilopoulos Y et al. Epidermal barrier dysfunction in atopic dermatitis. Journal of Investigative Dermatology 2009; 129: 1892-908.
5. Sprecher E, Chavanas S, DiGiovanna JJ et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: implications for mutation detection and first case of prenatal diagnosis. Journal of Investigative Dermatology 2001; 117: 179-87.
6. Smith FJ, Irvine AD, Terron-Kwiatkowski A et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nature Genetics 2006; 38: 337-42.
7. Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nature Genetics 2006; 38: 441-6.
8. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. British Medical Journal 2009; 339: 86-9.
9. Fallon PG, Sasaki T, Sandilands A et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nature Genetics 2009; 41: 602-8.
10. Scharschmidt TC, Man MQ, Hatano Y et al. Filaggrin deficiency confers a paracellular barrier abnormality that reduces inflammatory thresholds to irritants and haptens. Journal of Allergy and Clinical Immunology 2009; 124: 496-506.
11. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. Journal of Allergy and Clinical Immunology 2007; 120: 150-5.
12. Kim BE, Leung DY, Boguniewicz M et al. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clinical Immunology 2008; 126: 332-7.
13. Howell MD, Kim BE, Gao P et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. Journal of Allergy and Clinical Immunology 2009; 124: R7-12.
14. Inman AO, Olivry T, Dunston SM et al. Electron microscopic observations of the stratum corneum intercellular lipids in normal and atopic dogs. Veterinary Pathology 2001; 38: 720-3.
15. Piekutowska A, Pin D, Rème CA et al. Effects of a topically applied preparation of epidermal lipids on the stratum corneum barrier of atopic dogs. Journal of Comparative Pathology 2008; 138: 197-203.
16. Marsella R, Samuelson D, Doerr K. Transmission electron microscopic studies in an experimental model of canine atopic dermatitis. Veterinary Dermatology 2010; 21: 81-8.
17. Shimada K, Yoon JS, Yoshihara T et al. Increased transepidermal water loss and decreased ceramide content in lesional and non-lesional skin of dogs with atopic dermatitis. Veterinary Dermatology 2009; 20: 541-6.
18. Reiter LV, Torres SM, Wertz PW. Characterization and quantification of ceramides in the nonlesional skin of canine patients with atopic dermatitis compared with controls. Veterinary Dermatology 2009; 20: 260-6.
19. Chervet L, Galichet A, McLean WH et al. Missing C-terminal filaggrin expression, NFkappaB activation and hyperproliferation identify the dog as a putative model to study epidermal dysfunction in atopic dermatitis. Experimental Dermatology 2010; 19: e343-6.
20. Jackson HA, Hammerberg B. Evaluation of a spontaneous canine model of immunoglobulinE-mediated food hypersensitivity: dynamic changes in serum and fecal allergen-specific immunoglobulinE values relative to dietary change. Comparative Medicine 2002; 52: 316-21.
21. Olivry T, Kurata K, Paps JS et al. A blinded randomized controlled trial evaluating the usefulness of a novel diet (Aminoprotect Care) in dogs with spontaneous food allergy. Journal of Veterinary Medical Science 2007; 69: 1025-31.
22. Pucheu-Haston CM, Jackson HA, Olivry T et al. Epicutaneous sensitization with Dermatophagoides farinae induces generalized allergic dermatitis and elevated mite-specific immunoglobulinE levels in a canine model of atopic dermatitis. Clinical and Experimental Allergy 2008; 38: 667-79.
23. Hammerberg B, Bevier D, DeBoer DJ et al. Auto IgG anti-IgE and IgG×IgE immune complex presence and effects on ELISA-based quantitation of IgE in canine atopic dermatitis, demodectic acariasis and helminthiasis. Veterinary Immunology and Immunopathology 1997; 60: 33-46.
24. Masuda K, Yasuda N. The antibody against human CD25, ACT-1, recognizes canine T-lymphocytes in the G2/M and G0/G1 phases of the cell cycle during proliferation. Journal of Veterinary Medical Science 2008; 70: 1285-7.
25. Rissetto KC, Rindt H, Selting KA et al. Cloning and expression of canine CD25 for validation of an anti-human CD25 antibody to compare Tregulatory lymphocytes in healthy dogs and dogs with osteosarcoma. Veterinary Immunology and Immunopathology 2010; 135: 137-45.
26. Bengtsson A. The role of CD30 in atopic disease. Allergy 2001; 56: 593-603.
27. Bizikova P, Papich MG, Olivry T. Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Veterinary Dermatology 2008; 19: 348-57.
28. Kondo H, Ichikawa Y, Imokawa G. Percutaneous sensitization with allergens through barrier-disrupted skin elicits a Th2-dominant cytokine response. European Journal of Immunology 1998; 28: 769-79.
29. Spergel JM, Mizoguchi E, Brewer JP et al. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. Journal of Clinical Investigation 1998; 101: 1614-22.
30. Spergel JM, Mizoguchi E, Oettgen H et al. Roles of TH1 and TH2 cytokines in a murine model of allergic dermatitis. Journal of Clinical Investigation 1999; 103: 1103-11.
31. Strid J, Hourihane J, Kimber I et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. European Journal of Immunology 2004; 34: 2100-9.
32. Strid J, Callard R, Strobel S. Epicutaneous immunization converts subsequent and established antigen-specific Thelper type1 (Th1) to Th2-type responses. Immunology 2006; 119: 27-35.
33. Jin H, He R, Oyoshi M et al. Animal models of atopic dermatitis. Journal of Investigative Dermatology 2009; 129: 31-40.
34. Dickel H, Kamphowe J, Geier J et al. Strip patch test vs. conventional patch test: investigation of dose-dependent test sensitivities in nickel- and chromium-sensitive subjects. Journal of the European Academy of Dermatology and Venereology 2009; 23: 1018-25.
35. Langeveld-Wildschut EG, Vanmarion MW, Thepen T et al. Evaluation of variables influencing the outcome of the atopy patch test. Journal of Allergy and Clinical Immunology 1995; 96: 66-73.
36. Wood LC, Jackson SM, Elias PM et al. Cutaneous barrier perturbation stimulates cytokine production in the epidermis of mice. Journal of Clinical Investigation 1992; 90: 482-7.
37. Wood LC, Elias PM, Calhoun C et al. Barrier disruption stimulates interleukin-1 alpha expression and release from a pre-formed pool in murine epidermis. Journal of Investigative Dermatology 1996; 106: 397-403.
38. Wood LC, Stalder AK, Liou A et al. Barrier disruption increases gene expression of cytokines and the 55kD TNF receptor in murine skin. Experimental Dermatology 1997; 6: 98-104.
39. Shakib F, Ghaemmaghami AM, Sewell HF. The molecular basis of allergenicity. Trends in Immunology 2008; 29: 633-42.
40. Gough L, Schulz O, Sewell HF et al. The cysteine protease activity of the major dust mite allergen Derp1 selectively enhances the immunoglobulinE antibody response. Journal of Experimental Medicine 1999; 190: 1897-901.
41. Shakib F, Gough L. The proteolytic activity of Derp1 selectively enhances IgE synthesis: a link between allergenicity and cysteine protease activity. Clinical and Experimental Allergy 2000; 30: 751-2.
42. Wan H, Winton HL, Soeller C et al. Quantitative structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house dust mite allergen Derp1. Clinical and Experimental Allergy 2000; 30: 685-98.
43. Wan H, Winton HL, Soeller C et al. The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus. Clinical and Experimental Allergy 2001; 31: 279-94.
44. Pucheu-Haston CM, Shuster D, Olivry T et al. A canine model of cutaneous late-phase reactions: prednisolone inhibition of cellular and cytokine responses. Immunology 2006; 117: 177-87.
45. Pucheu-Haston CM. Role of epicutaneous exposure to Dermatophagoides farinae in the development of IgE-dependent and independent allergic dermatitis in the dog. PhD Thesis, NC State University, 2006: 1-140.
46. Chamlin SL, Frieden IJ, Fowler A et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Archives of Dermatology 2001; 137: 1110-2.
47. Chamlin SL, Kao J, Frieden IJ et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. Journal of the American Academy of Dermatology 2002; 47: 198-208.
48. Wiren K, Nohlgard C, Nyberg F et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. Journal of the European Academy of Dermatology and Venereology 2009; 23: 1267-72.
49. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. Journal of Drugs in Dermatology 2009; 8: 1106-11.
50. Billmann-Eberwein C, Rippke F, Ruzicka T et al. Modulation of atopy patch test reactions by topical treatment of human skin with a fatty acid-rich emollient. Skin Pharmacology and Applied Skin Physiology 2002; 15: 100-4.
51. Olivry T, DeBoer DJ, Favrot C et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Veterinary Dermatology 2010; 21: 233-48.